Effects of histidine-proline-rich glycoprotein on plasminogen activation in solution and on surfaces

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 8, 2004, Pages 663-672

  Borza, Dorin Bogdan ^a,b   Shipulina, Natalia V ^a   Morgan, William T ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibrinogen; Fibrinolysis; Histidine proline rich glycoprotein; Plasminogen; Tissue plasminogen activator

Indexed keywords

FIBRINOGEN; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; HISTIDINE PROLINE RICH GLYCOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADSORPTION; ARTICLE; CATALYSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

ADSORPTION; CATALYSIS; GLYCOPROTEINS; GLYCOSAMINOGLYCANS; HISTIDINE; HUMANS; PEPTIDE FRAGMENTS; PLASMINOGEN; PROLINE; PROTEIN BINDING; SOLUTIONS; SURFACE PROPERTIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 10044264536     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200412000-00006     Document Type: Article

References (55)

1. Lijnen HR, Van Hoef B, Collen D. Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma. Thromb Haemost 1984; 51:266-268.
2. Burch MK, Blackburn MN, Morgan WT. Further characterization of the interaction of histidine-rich glycoprotein with heparin: evidence for the binding of two molecules of histidine-rich glycoprotein by high molecular weight heparin and for the involvement of histidine residues in heparin binding. Biochemistry 1987; 26:7477-7482.
3. Peterson CB, Morgan WT, Blackburn MN. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. J Biol Chem 1987; 262:7567-7574.
4. Borza DB, Morgan WT. Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by pH and metals. J Biol Chem 1998; 273:5493-5499.
5. Kluszynski BA, Kim C, Faulk WP. Zinc as a cofactor for heparin neutralization by histidine-rich glycoprotein. J Biol Chem 1997; 272:13541-13547.
6. Fu CL, Horne MK, 3rd. Histidine-rich glycoprotein plus zinc to neutralize heparin. J Lab Clin Med 2002; 139:211-217.
7. Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255:10214-10222.
8. Saez CT, Jansen GJ, Smith A, Morgan WT. Interaction of histidine-proline-rich glycoprotein with plasminogen: effect of ligands, pH, ionic strength, and chemical modification. Biochemistry 1995; 34:2496-2503.
9. Borza DB, Morgan WT. Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J Biol Chem 1997; 272:5718-2726.
10. Borza DB, Tatum FM, Morgan WT. Domain structure and conformation of histidine-protine-rich glycoprotein. Biochemistry 1996; 35:1925-1934.
11. Morgan WT. The histidine-rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals. Biochemistry 1985; 24:1496-1501.
12. Ranieri-Raggi M, Martini D, Sabbatini AR, Moir AJ, Raggi A. Isolation by zinc-affinity chromatography of the histidine-proline-rich-glycoprotein molecule associated with rabbit skeletal muscle AMP deaminase. Evidence that the formation of a protein-protein complex between the catalytic subunit and the novel component is critical for the stability of the enzyme. Biochim Biophys Acta 2003; 1645:81-88.
13. Silverstein RL, Leung LL, Harpel PC, Nachman RL. Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest 1985; 75:2065-2073.
14. Jespersen J, Gram J, Bach E. A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. Thromb Haemost 1984; 51:99-102.
15. Castaman G, Ruggeri M, Burei F, Rodeghiero F. High levels of histidine-rich glycoprotein and thrombotic diathesis. Report of two unrelated families. Thromb Res 1993; 69:297-305.
16. Shigekiyo T, Ohshima T, Oka H, Tomonari A, Azuma H, Saito S. Congenital histidine-rich glycoprotein deficiency. Thromb Haemost 1993; 70:263-265.
17. Munkvad S. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Dan Med Bull 1993; 40:383-408.
18. Hennis BC, Van Boheemen PA, Koeleman BP, Boomsma DI, Engesser L, Van Wees AG, et al. A specific allele of the histidine-rich glycoprotein (HRG) locus is linked with elevated plasma levels of HRG in a Dutch family with thrombosis. Br J Haematol 1995; 89:845-852.
19. Rao AK, Sheth S, Kaplan R. Inherited hypercoagulable states. Vasc Med 1997; 2:313-320.
20. Shigekiyo T, Yoshida H, Matsumoto K, Azuma H, Wakabayashi S, Saito S, et al. HRG Tokushima: molecular and cellular characterization of histidine-rich glycoprotein (HRG) deficiency. Blood 1998; 91:128-133.
21. Ehrenforth S, Junker R, Koch HG, Kreuz W, Munchow N, Scharrer I, Nowak-Gottl U. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. Eur J Pediatr 1999; 158(suppl 3):S97-S104.
22. Kuhli C, Scharrer I, Koch F, Hattenbach LO. Recurrent retinal vein occlusion in a patient with increased plasma levels of histidine-rich glycoprotein. Am J Ophthalmol 2003; 135:232-234.
23. Chu AJ, Mathews ST. Poly-L-histidine downregulates fibrinolysis. Blood Coagul Fibrinolysis 2003; 14:627-632.
24. Castellino FJ, Powell JR. Plasminogen isolation by affinity chromatography. Methods Enzymol 1981; 80:365-378.
25. Haddeland U, Sletten K, Bennick A, Nieuwenhuizen W, Brosstad F. Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t-PA-catalysed plasminogen activation. Thromb Haemost 1996; 75:326-331.
26. Levine RL. Ischemia: from acidosis to oxidation. FASEB J 1993; 7:1242-1246.
27. 2- Glykoproteins (CM-Protein I) [Human serum proteins with high affinity for carboxymethylcellulose. II. Physico-chemical and immunological characterization of a histidine-rich 3,8S-α2-glycoportein (CM-protein I)]. Hoppe-Seyler's Z Physiol Chem 1972; 353:1133-1140.
28. Leung L. Histidine-rich glycoprotein: an abundant plasma protein in search of a function [Editorial; Comment]. J Lab Clin Med 1993; 121:630-631.
29. Shigekiyo T, Kanazuka M, Azuma H, Ohshima T, Kusaka K, Saito S. Congenital deficiency of histidine-rich glycoprotein: failure to identify abnormalities in routine laboratory assays of hemostatic function, immunologie function, and trace elements [see comments]. J Lab Clin Med 1995; 125:719-723.
30. Zehnder JL, Leung LL. Histidine-rich glycoprotein: is there a role in hemostasis or immune function? [Editorial; Comment]. J Lab Clin Med 1995; 125:682-683.
31. Kluft C, Los P. Modified crossed immunoelectrophoresis to study with whole plasma the reversible complex formation of histidine-rich glycoprotein with plasminogen. Thromb Haemost 1988; 60:411-414.
32. Lijnen HR, Jacobs G, Collen D. Histidine-rich glycoprotein in a normal and a clinical population. Thromb Res 1981; 22:519-523.
33. Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemost 1982; 48:283-285.
34. Lijnen HR, DeCock F, Collen D. Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy. Thromb Res 1981; 23:121-131.
35. Lijnen HR, Collen D. Turnover of histidine-rich glycoprotein during heparin administration in man. Thromb Res 1983; 30:671-676.
36. Goodnough LT, Saito H, Bell WR, Heimburger N. Histidine-rich glycoprotein and changes in the components of the fibrinolytic system after streptokinase therapy in patients with pulmonary thromboembolism. Am J Hematol 1985; 19:245-253.
37. Smith A, Nuiry I, Morgan WT. Proteolysis of histidine-rich glycoprotein in plasma and in patients undergoing thrombolytic therapy. Thromb Res 1985; 40:653-661.
38. Engesser L, Kluft C, Briet E, Brommer EJ. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67:355-358.
39. Hoffmann JJ, Bonnier JJ. Histidine-rich glycoprotein in thrombolytic therapy: has it clinical relevance? Blood Coagul Fibrinolysis 1991; 2:237-241.
40. Falkon L, Gari M, Montserrat I, Borrell M, Fontcuberta J. Familial elevation of plasma histidine-rich glycoprotein. A case associated with recurrent venous thrombosis and high PAI-1 levels. Thromb Res 1992; 66:265-270.
41. Hoffmann JJ, Hennis BC, Kluft C, Vijgen M. Hereditary increase of plasma histidine-rich glycoprotein associated with abnormal heparin binding (HRG Eindhoven). Thromb Haemost 1993; 70:894-899.
42. Ehrenforth S, Aygoren-Pursun E, Hach-Wunderle V, Scharrer I. Prevalence of elevated histidine-rich glycoprotein in patients with thrombophilia - a study of 695 patients. Thromb Haemost 1994; 71:160-161.
43. Souto JC, Gari M, Falkon L, Fontcuberta J. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemost 1996; 75:374-375.
44. Schielen WJ, Adams HP, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. Blood Coagul Fibrinolysis 1991; 2:465-470.
45. Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994; 33:13918-13927.
46. Olsen HM, Parish CR, Altin JG. Histidine-rich glycoprotein binding to T-cell lines and its effect on T-cell substratum adhesion is strongly potentiated by zinc. Immunology 1996; 88:198-206.
47. Haddeland U, Sletten K, Bennick A, Brosstad F. Freeze-dried fibrinogen or fibrinogen in EDTA stimulate the tissue-type plasminogen activator-catalysed conversion of plasminogen to plasmin. Blood Coagul Fibrinolysis 1994; 5:575-581.
48. DeLa Cadena RA, Colman RW. Structure and functions of human kininogens. Trends Pharmacol Sci 1991; 12:272-275.
49. Villanueva GB, Leung L, Bradford H, Colman RW. Conformation of high molecular weight kininogen: effects of kallikrein and factor XIa cleavage. Biochem Biophys Res Commun 1989; 158:72-79.
50. Schapira M, Scott CF, Colman RW. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors. Trans Assoc Am Physicians 1981; 94:190-197.
51. Goerges AL, Nugent MA. pH regulates vascular endothelial growth factor binding to fibronectin: a mechanism for control of extracellular matrix storage and release. J Biol Chem 2004; 279:2307-2315.
52. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113:38-48.
53. Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 2001; 107:45-52.
54. Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 2002; 62:5344-5350.
55. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004; 64:599-605.